Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (March 2022)
16 slides from Alembic Pharmaceuticals's investor presentation, March 2022
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – March 2022
Alembic Pharmaceuticals Limited Investor presentation – March 2022 BSE & NSE: APLLTD
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 3: Financial Highlights
Financial Highlights Particulars Q4 FY22 Q4 FY21 Growth FY22 FY21 INR Bn Growth Net Sales 14.16 12.80 11% 53.06 53.93 -2% EBIDTA Pre R&D 4.31 5.40 -20% 16.64 22.52 -26% Margin % 30% 42% 31% 42% R&D 3.50 1.95 80% 8.38 6.70 25% R&D % 25% 15% 16% 12% EBIDTA Post R&D 1.64 3.59 -54% 9.55 16.31 -41% Margi
Slide 4: Acquisition of Aleor
Acquisition of Aleor Summary : Alembic Pharmaceuticals has acquired the balance Q4FY22 Financial Highlights with and without Aleor impact 40% stake in Aleor Dermaceuticals from its JV Partner Orbicular INR Bn Pharmaceutical Technologies. With this, Aleor Dermaceuticals has become wholly owned subsid
Slide 5: Business snapshot – Q4FY22
Business snapshot – Q4FY22 Formulations Generics Branded API Total US Ex-US India Revenue Q4FY22 (INR Bn) 5.57 1.88 4.49 2.22 14.16 API Vet 16% 16% 4% 39% Generics Q4FY22 Revenue 53% Acute Contribution 10% Branded 32% 13% Speciality 17% Growth Q4FY22 -19% 17% 25% 4% 11% over Q4FY21 Growth Q4FY22 -3%
Slide 6: Business snapshot – YTDFY22
Business snapshot – YTDFY22 Formulations Generics Branded API Total US Ex-US India Revenue YTDFY22 (INR Bn) 16.66 7.75 19.26 9.39 53.06 API Vet 18% 18% 4% Generics YTDFY22 Revenue 31% 46% Contribution Acute 13% 15% Branded Speciality 19% 36% Growth YTDFY22 -23% -2% -2% over YTDFY21 0% 29% • Well-est
Slide 7: US Generic
US Generic INR Bn Revenue – Q4 FY22 INR Bn Revenue – Last 5 Years CAGR - 16% 5.57 21.63 4.75 19.76 16.66 12.88 9.20 Q4FY21 Q4FY22 FY18 FY19 FY20 FY21 FY22 Approved ANDAs Injectable Derma 2 Inhalation 19 1 ➢ US business has posted sequential growth of 42% in the quarter backed by market-share gain in
Slide 8: Ex-US Generics
Ex-US Generics Revenue : Q4 FY22 INR Bn Revenue – Last 5 Years INR Bn 2.33 CAGR - 28% 1.88 7.79 7.75 4.94 4.97 Q4FY21 Q4FY22 ➢ The Ex-US business has performed well in spite of a high base of last 2.86 year. ➢ The Ex-US business de-grew marginally at 0.5% in FY22. ➢ New launches on track to drive gr
Slide 9: API
API Revenue : Q4 FY22 INR Bn Revenue – Last 5 Years INR Bn 4% ↑ 2.22 CAGR - 10% 2.14 9.55 9.39 7.71 7.08 6.51 Q4FY21 Q4FY22 ➢ API business had a high base of Azithromycin in last year and hence business de-grew by 2% in FY22. ➢ Rest of the portfolio continues to do well. ➢ 8 USDMFs filed in FY22. 12
Slide 10: R&D: Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 15.8% 37 Filing 8.0 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 23 20 21 18 19 4.0 8.4 11 Filings & 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.1 contributed by acquisition of
Slide 11: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Nov’2
Slide 12: Branded Business
Branded Business Revenue – Q4 FY22 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 19.3 4.49 3.58 0.53 15.0 13.8 14.3 Vet 0.46 1.48 12.7 Acute 0.94 Speciality 2.18 2.47 Q4FY21 Q4FY22 FY18 FY19 FY20 FY21 FY22 Marketing organization Key achievements ➢ 5500 + Marketing team ➢ Performance in Q4FY22 is l
Slide 13: Therapy-wise Performance Q4 FY22
Therapy-wise Performance Q4 FY22 Q4 FY22 Q4 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 7 1.9 3 8 14 1.9 18 8 Gastrology 10 1.4 13 10 16 1
Slide 14: Therapy-wise Performance YTD FY22
Therapy-wise Performance YTD FY22 FY22 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 11 1.8 5 9 14 1.9 15 12 Gastrology 18 1.4 22 18 5 1.4 1
Slide 15: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 31.31 9.55 8.75 5.84 5.46 6.42 4.13 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 CAGR - 14% CAGR - 10% CAGR - 7% EBIDTA margin % Cape
Slide 16: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Investor Presentation (March 2022) on 6ix